But, none of the molecular markers, including E-cadherin, P53, and epidermal growth factor receptor (EGFR), have been identified as definite predictors of ALNM in breast cancer.5–8 Thus, we assessed whether these molecular and clinical markers could be used to predict positive ALNM in early breast cancer. The gene discussed is EGFR; the disease is breast cancer.